Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DBPR112
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Anbogen Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
Details : ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.
Brand Name : ABT-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : DBPR112
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Anbogen Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Cancer Drug Delivery System Receives US FDA Approval for Trials
Details : DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.
Brand Name : DBPR115
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2021
LOOKING FOR A SUPPLIER?
Reset All
